Lung and general health effects of Toll-like receptor-4 (TLR4)-interacting SPA4 peptide.
Shanjana AwasthiNegar RahmanBin RuiGaurav KumarVibhudutta AwasthiMelanie BreshearsStanley KosankePublished in: BMC pulmonary medicine (2020)
These findings provide an initial toxicity profile of SPA4 peptide. Intratracheal administration of escalating doses of SPA4 peptide does not induce any significant toxicity at tissue and organ levels. However, treatment with a dose of 50 μg SPA4 peptide, comparable to 2.5 μg/g body weight, alleviates LPS-induced lung inflammation.